Sanofi's shift towards innovative medicines will not be painless for its employees. The French pharmaceutical laboratory announced to union organizations on March 28 its intention to cut 331 positions in its research and development teams dedicated to oncology. Sanofi is withdrawing from this area after several recent failures, and is now focusing its efforts on immunology, where it is obtaining promising results. Its star drug, Dupixent, for example, already acts on the immune system to treat atopic dermatitis or asthma.
70% of ongoing oncology projects will be stopped. “
We must reprioritize our portfolio to be able to invest more in immunology
,” explains Audrey Derveloy, president of Sanofi France.
Our latest results show that we cannot be a leader in oncology, a field where research is also costly. Some projects, which were promising, are no longer so…
This article is reserved for subscribers. You have 79% left to discover.
Do you want to read more?
Unlock all items immediately.
TEST FOR €0.99
Already subscribed? Log in